Subject
Oncology,Hematology,Pediatrics, Perinatology and Child Health
Reference18 articles.
1. Desai A. Entrectinib in children, adolescents and young adults with extracranial solid or primary CNS tumours harbouring NTRK1/2/3, ROS1, or ALK fusions: Updated data from STARTRK-NG. SIOP, 2022, abstr. 440.
2. Okamura R., Boichard A., Kato S., Sicklick J.K., Bazhenova L., Kurzrock R. Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. JCO Precis Oncol. 2018;2018:PO.18.00183. doi: 10.1200/PO.18.00183.
3. Aepala M.R., Peiris M.N., Jiang Z., Yang W., Meyer A.N., Donoghue D.J. Nefarious NTRK oncogenic fusions in pediatric sarcomas: too many to TRK. Cytokine Growth Factor Rev. 2022;68:93–106. doi: 10.1016/j.cytogfr.2022.08.003.
4. Hong D.S., DuBois S.G., Kummar S., Farago A.F., Albert C.M., Rohrberg K.S., van Tilburg C.M., Nagasubramanian R., Berlin J.D., Federman N., Mascarenhas L., Geoerger B., Dowlati A., Pappo A.S., Bielack S., Doz F., McDermott R., Patel J.D., Schilder R.J., Tahara M., Pfi ster S.M., Witt O., Ladanyi M., Rudzinski E.R., Nanda S., Childs B.H., Laetsch T.W., Hyman D.M., Drilon A. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21(4):531–40. doi: 10.1016/S1470-2045(19)30856-3.
5. Doz F., van Tilburg C.M., Geoerger B., Højgaard M., Øra I., Boni V., Capra M., Chisholm J., Chung H.C., DuBois S.G., Gallego-Melcon S., Gerber N.U., Goto H., Grilley-Olson J.E., Hansford J.R., Hong D.S., Italiano A., Kang H.J., Nysom K., Thorwarth A., Stefanowicz J., Tahara M., Ziegler D.S., Gavrilovic I.T., Norenberg R., Dima L., De La Cuesta E., Laetsch T.W., Drilon A., Perreault S. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro Oncol. 2022;24(6):997–1007. doi: 10.1093/neuonc/noab274.